Herve Ghesquieres

Le Chesnay, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 233 publications

Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.

Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 17, 2026

Marginal Zone Lymphoma With T-Follicular Helper Hyperplasia: Paving the Way for New Concepts in Cellular Plasticity and Unveiling Histopathologic Pitfalls.

Marginal Zone Lymphoma With T-Follicular Helper Hyperplasia: Paving the Way for New Concepts in Cellular Plasticity and Unveiling Histopathologic Pitfalls.

Journal: The American journal of surgical pathology

Published: May 14, 2026

Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.

Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.

Journal: British journal of haematology

Published: May 05, 2026

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.

Journal: Haematologica

Published: May 04, 2026

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

Journal: Haematologica

Published: April 12, 2026

Rituximab-induced hypogammaglobulinemia in autoimmune cytopenia and associated diseases.

Rituximab-induced hypogammaglobulinemia in autoimmune cytopenia and associated diseases.

Journal: La Revue de medecine interne

Published: April 08, 2026

Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma.

Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma.

Journal: Clinical pharmacology and therapeutics

Published: April 04, 2026

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Journal: Blood

Published: April 01, 2026

Oncogenic Role of BCL6 Rearrangement: A Focus on Follicular and Marignal Zone Lymphomas.

Oncogenic Role of BCL6 Rearrangement: A Focus on Follicular and Marignal Zone Lymphomas.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: February 09, 2026

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Journal: Hematological oncology

Published: February 05, 2026

Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.

Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.

Journal: Blood

Published: January 29, 2026

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Journal: Blood

Published: January 29, 2026

Showing 1-12 of 233

Last Updated: 09/26/2026